RT Journal Article
SR Electronic
T1 Variation across population subgroups of COVID-19 antibody testing performance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.14.20191833
DO 10.1101/2020.09.14.20191833
A1 Brantley, Halley L.
A1 Yoo, Richard M.
A1 Jones, Glen I.
A1 Stock, Marel A.
A1 Park, Peter J.
A1 Sheils, Natalie E.
A1 Kohane, Isaac S.
YR 2020
UL http://medrxiv.org/content/early/2020/09/16/2020.09.14.20191833.abstract
AB Understanding variations in the performance of serological tests for SARS-CoV-2 across varying demographics is relevant to clinical interpretations and public policy derived from their results. Appropriate use of serological assays to detect anti-SARS-CoV-2 antibodies requires estimation of their accuracy over large populations and an understanding of the variance in performance over time and across demographic groups. In this manuscript we focus on anti-SARS-CoV-2 IgG, IgA, and IgM antibody tests approved under emergency use authorizations and determine the recall of the serological tests compared to RT-PCR tests by Logical Observation Identifiers Names and Codes (LOINCs). Variability in test performance was further examined over time and by demographics. The recall of the most common IgG assay (LOINC 94563-4) was 91.2% (95% CI: 90.5%, 91.9%). IgA (LOINC 94562-6) and IgM (94564-2) assays performed significantly worse than IgG assays with estimated recall rates of 20.6% and 27.3%, respectively. A statistically significant difference in recall (p = 0.019) was observed across sex with a higher recall in males than females, 92.1% and 90.4%, respectively. Recall also differed significantly by age group, with higher recall in those over 45 compared to those under 45, 92.9% and 88.0%, respectively (p< 0.001). While race was unavailable for the majority of the individuals, a significant difference was observed between recall in White individuals and Black individuals (p = 0.007) and White individuals and Hispanic individuals (p = 0.001). The estimates of recall were 89.3%, 95.9%, and 94.2% for White, Black, and Hispanic individuals respectively.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and deemed exempt by the institutional review board of UnitedHealth Group.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are proprietary and are not available for public use but can be made available under a data use agreement to confirm the findings of the current study. The statistical code is available from the first author.